Keep Informed Judgment in Funding

The most controversial subject in academic science policy recently is the dispute over the effects of the growing practice by which institutions seek and receive from Congress specially earmarked appropriations for research facilities. To a remarkable degree, decisions about who should be funded to do science have been made on an essentially nonpolitical basis, even though government has been the main patron. There has never been the slightest doubt that Congress has had the power and the right

Written byRobert Rosenzweig
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

To a remarkable degree, decisions about who should be funded to do science have been made on an essentially nonpolitical basis, even though government has been the main patron. There has never been the slightest doubt that Congress has had the power and the right to decide on the disposition of every dollar of federal research appropriations. Nor has there been any doubt that university people have the "right" guaranteed them by the Constitution to petition Congress to meet their needs. The fact that both have chosen, with relatively marginal exceptions, not to do so has enabled American science to avoid both automatic funding formulas and decisions based on political favoritism.

I do not include among the exceptions national facilities like the great accelerator centers. They are not marginal, and neither are they exceptions. While decisions about the siting of those centers have had a strong political component, the political ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies